Trevi Therapeutics, Inc. (TRVI) research
Trevi Therapeutics, Inc.- Sector
- Pharmaceuticals
- Last price
- $13.91
- As of
Trevi Therapeutics, Inc. (TRVI): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for TRVI. Method and limitations.
Share the TRVI intelligence card
See the full TRVI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TRVI on one page. Preview it with sample data, then open it live with a free account.
Preview the TRVI dossierActive signals for TRVI
- highINSTITUTIONAL_EXIT
VIKING GLOBAL INVESTORS LP cut 52% of TRVI (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +56% to TRVI (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 54% of TRVI (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 12.6% - EPS $-0.09 vs $-0.103 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 15.4% - EPS $-0.09 vs $-0.078 estimate
FREE, NO ACCOUNT
Every signal on TRVI, as it fires
You are seeing 5 of 9 signals recorded on TRVI since 2026-05-17.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TRVI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 89532M101 · 2026Q2 | $28.8M | 0.08% | , |
| D. E. Shaw & Co., Inc.CUSIP 89532M101 · 2026Q2 | $5.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TRVI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TRVI against its peers
TRVI's return on equity of -23.3% ranks in the 43rd percentile of 21 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | TRVI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 545M | n/a | 22 |
| Gross margin | n/a | 53.3% | n/a | 7 |
| Operating margin | n/a | 5.6% | n/a | 20 |
| Net margin | n/a | 0.2% | n/a | 21 |
| Return on equity | -23.3% | -9.3% | 43 | 21 |
| P / E | n/a | 15.0x | n/a | 10 |
Peers (25): NKTR, NUVB, BHC, GPCR, HRMY, ANIP, XERS, SUPN, OCUL, INVA, PAHC, OMER, OGN, TARS, AMLX, AMPH, ANRO, PCRX, ALMS, LQDA, ESPR, ACRS, COLL, AMRX, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TRVI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TRVI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TRVI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.